reason report
biopharma catalyst tracker top catalyst
bottom line catalyst tracker coverag provid detail
upcom event expect within biopharma coverag
sortabl spreadsheet calendar timelin stock impact
contribut analyst coverag name top catalyst expect next
three month highlight analyst within report
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
statement statu
believ updat statu hsr hart-scott-rodino clearanc could provid
hsr clearanc agn
clariti expect timelin closur mp acquisit well
need potenti divestitur overlap product area given ftc perceiv
heighten scrutini toward recent biopharma event type could impact
believ risk/reward event skew upsid
data readout
trial stop earli strong efficaci trial continu
view likelihood upsid low chanc downsid
like chanc
assum probabl success inclisiran estim risk-adjust
line result orion
peak sale inclisiran yield peak royalti
 studi
patient
fda adcom makena
believ posit adcom rule allow makena remain market drive
upsid stock
date believ risk/reward skew posit given initi american
result non-smal cell
monotherapi cohort
world confer
societi clinic oncolog data show respons rate evid
durabl benefit could address concern potenti develop resist
coval inhibit kra activ could result nsclc
probabl success po increas allow valuat fulli
captur potenti ww peak sale indic alon
correspond stock movement
fda adcom vascepa
believ posit adcom rule lead snda approv drive
upsid stock
upcom present american societi hematolog includ
escal data arq
durabl data number patient treat arq focu chronic
lymphocyt leukemia cll richter transform recal arql present
inhibitor cell
data european hematolog associ eha june highlight partial
respons pr achiev cll patient mutat data
includ month addit follow-up respond eha base
time two confer overal continu view arq
excit asset arql pipelin sourc continu upsid stock
valu attribut arq today begin
indic arq could play role chronic lymphocyt leukemia cll
remain dynam competit continu see potenti long-term
appreci arq becom de-risk futur clinic updat
date upsid possibl nearli baselin virologically-
week phase data
hepat viru hbv
american associ
studi liver
suppress hbv patient reach hbv dna target undetect plasma week
steadi hbeag hepat antigen hbsag hepat surfac antigen
observ week would increas investor expect standard po
cure possibl opposit see downsid cash valu possibl
data uncompel signific antigen declin investor abandon cure
hypothesi entir maintain po cure market
appear price po
voclosporin ln remain controversi follow patient death
imbal seen aura-lv studi suspect caus identifi site
select asia poor random aurora trial design mimic
aura-lv show similarli robust efficaci profil exclud question trial
site fuel posit aura-lv data posit outcom aurora
could redefin standard care soc ln offer signific upsid today
first materi readout provid hint whether fast-follow pfe
result open label
vyndaqel competit clinic profil current assum probabl
extens ole
patient attr
success risk-adjust peak sale
top-lin data phase
one signific binari catalyst target oncolog univers beigen
aspen trial
r/r waldenstrom wm
anticip top-lin data phase aspen trial could enabl
first nda file zanubrutinib waldenstrom earli expect
investor focus zanu superior imbruvica base complet
respons rate cr good partial respons vgpr well safety/toler
profil particularli atrial fibril major hemorrhag rate see
signific catalyst bgne share potenti movement /- best/worst
overhang valrox clear definit plan file valrox
week data pt
us eu believ phase data vosoritid
could meaning open bmrn next market opportun phase studi
vosoritid could garner investor interest view power robustli
detect cm/yr annual growth veloc despit investor question clinic
relev height benefit month treatment medacorp kol
check suggest increment height gain would consid meaning even
proport growth achiev indic approv therapi gradual
label expans includ younger pt possibl via on-going studi bode well
program view
investor caution receptor inhibit mechan
believ current valuat reflect aav minim valu ascrib follow-on
program glomerulopathi focal segment glomerulosclerosi fsg
posit outcom advoc direct impact aav po may offer re-
calibr investor sentiment avacopan relatedli advoc outcom may
impact ifrx mp given pursuit aav
share sold follow initi roxadustat data disclosur
present american
societi nephrolog
earn call cardiovascular cv event non-dialysi depend ndd
chronic kidney diseas ckd patient investor significantli discount
contribut ndd indic share although stock partial
rebound recent low share remain range-bound investor await
clariti prospect demonstr statist non-inferior prior anticip
bla file octob believ demonstr non-inferior american societi
nephrolog could increas investor confid head bla repres
upsid current stock price share fulli reflect
valu us ndd opportun
date potenti move posit data base gilead stock
asset phase
retrac pre-selonsertib failur trade rang januari would includ
valu nash portfolio stock littl nash valu see limit
downsid neg data percept asset best class lack
fxr american
associ studi
liver diseas
synergist efficaci mechan
appear view skeptic street base post-hoc analysi
elafibranor nash
use phase studi confid street believ stock
potenti upsid event success depend efficaci rate
downsid would like least within coverag univers op also
like larg mover data move direct gnft event
success less downsid risk
stock remain weak reflect investor caution
competitor data hereditari angioedema nr believ posit
phase data differenti reignit investor optim
effect oral medicin address acut market moreov phase
plan acut set delay chanc catch-
potenti becom first-in-class oral medicin
top-lin data
overal believ boston studi like posit neg base
encourag phase stomp data compel preced triplet
selinexor
regimen nearli alway beat doublet regimen mm feedback medacorp
kol fact fda seen interim data boston studi
facilit selinexor acceler approv rrmm patient least prior
therapi howev remain one controversi name coverag
univers top-lin boston data repres potenti binari catalyst
stock valid concern investor view signific downsid risk
stock studi fail beyond clinic develop risk also
commerci risk investor debat size selinexor opportun
competit mm landscap best bull bear worst case scenario price
target goe respect recent preview upcom
readout analyz variou data scenario
remain cautious optimist ahead second sophia overal surviv os
interim readout recal investor disappoint first interim os data
present american societi clinic oncolog link link
medacorp kol check suggest os benefit like need approv
link link link view os benefit ultim import commerci
uptak partnership discuss longer term believ find partner
invest develop margetuximab beyond sophia set metastat breast
cancer mbc import stori earlier line set breast cancer
interim readout
surviv data
combin
chemotherapi
go/no-go decis
direct impact expect minim third major io-io immuno-
proceed phase
oncolog combin random data import read potenti io add-on
phase trial
melanoma
detail phase data
downsidedata indic near-term competit threat nivo ipi
ipi
top-lin posit
pembrolizumab /- chemotherapi posit nsclc
think risk/reward skew upsid strong proof-
open-label studi
of-concept data worst case scenario rse studi
refract statu
initi clinic data
first clinic data expect present medic meet
phase trial
like tripl meet boston octob initi data
promis strong monotherapi activ note lung cancer nsclc
initi respons observ colorect appendic cancer respons
particularli promis given activ seen sub-optimal monotherapi dose
believ level mirati initi data exceed activ shown
rather demonstr monotherapi activ obvious inferior safeti
toler also key medacorp kol believ optim activ
class like seen combin target agent and/or i/o
pt vs current repres optimist view
odd bardoxolon program outcom cardin mark first phase top-lin
readout rare chronic kidney diseas ckd impli stock move reflect
approv alport syndrom includ cardin data full approv
also read-through autosom domin polycyst kidney diseas adpkd
current test phase falcon trial moreov base posit phase phoenix
data result cardin may implic rare form ckd like iga
initi clinic data
initi clinic data rubi cell therapi platform base engin red blood cell
phase studi
expect initi data phase studi
pku manag recent indic initi dataset
patient worth data addit guid disclos data
product trans-cinnam acid tca biomark activ although phe reduct
data could present observ believ investor view tca data
insuffici proof-of-concept absenc phenylalanin phe reduct data
howev regardless specif activ data disclos still view initi
clinic data import clear us pku
stori integr part invest thesi valuat potenti broad
applic platform across multipl diseas area includ oncolog rare
diseas autoimmun diseas spoken manag conduct
deeper dive rubi platform lead asset ahead initi clinic data link
note manag convers highlight confid ahead pku data phe-
ling red-i initi red cell therapi data preview pku data best
case scenario see upsid pt worst case scenario see
downsid pt
top-lin data
seattl genet anticip top-line data pivot trial evalu
tucatinib
tucatinib metastat breast cancer medacorp kol
spoken express enthusiasm agent specif target
spare epiderm growth factor receptor egfr believ may
efficaci profil similar puma nerlynx without egfr-rel toxic diarrhea
howev kol spoken cautiou around trial design note
herceptin capecitabin rel high bar third line mbc rel
tykerb use capecitabin arm may blunt purport
benefit tucatinib posit data tucatinib could expand pipelin
thesi beyond adcetri ev see potenti movement /- top-line data
ph interim data
microdystrophin competit heat optimist
therapi duchenn
sldb dystrophin express function data readout could set
apart increas po add upsid
current pt upsid market price anticip
lead clinic asset failur could result trade cash
downsid cash-per-share deriv impact
visibl opioid
op rule oklahoma case and/or potenti addit settlement multi-
litig mdl
track case start
district litig mdl could provid visibl magnitud financi impact
drug manufactur believ addit settlement continu point
overal liabil along line recent endo settlement see expans
sector multipl drive upsid doubl digit
final analysi phase
substanti binari impact either downsid near cash
trial
upsid expect failur
fc r/r high grade
initi phase
highli short stock potenti de-risk regulatori event bear believ stock
studi nash
clear studi start share potenti move sever dollar higher
event clean studi design valu driver share
first interim readout open-label extens studi suvodirsen patient biopsi
dystrophin express
patient
week platform defin data posit manag expect
file acceler approv
fda approv lead
believ gvoke hypopen get approv septemb pdufa
drive upsid stock
date believ demonstr function muscl benefit could
function data
dystrophi fshd
signific catalyst advanc wholli own asset although
neutral stanc expect outcom believ data could impact
stock current assign fshd valu po
believ risk/reward event skew downsid
resubmiss dravet
file sept expect high likelihood signific delay
unforeseen issu low likelihood believ resubmiss track
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
open label studi
confirm
hmb uterin
nda file
phase trial
progress form ms
primari complet
primari complet
phase trial
complet aug/sep-
open label studi
sclc high
end phase ii meet
end phase ii meet
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
mild
data common wart
phase data
safeti respons
mono combo
keytruda
nsclc mono
combo
top-lin data
preclin data
present
result scchn
escal pembro
tnbc other
scchn
expans adu-
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
tnbc other
dose esclat
report data
report data igan
announc
potenti cga
start r/r ptcl
transform
phase trial ag-
mtap delet
data phiii
activ trial pkd
patient receiv
data phiii
activate-t trial
detail data
tibsovo
submit snda
tibsovo
base claridhi
fda action bla
launch expect
phase data releas
phase data chronic
fda action nda
launch expect
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
start phase asia
canada
interim analysi
monotherapi
fda action nda
launch expect
start phase studi
schizophrenia
singl agent
combin stage
singl agent
combin stage
present top-line
result
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
add-on current
european hear
combin waiha
pv ph data
later
combin waiha
pv ph data
later
clinic poc studi
initi phase
endpoint prelud
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
bridg trial pnh
top line data
complet
enrol phase
top line data
phase trial
adcom discuss
patent litig
patent litig trial
start vs dr reddi
file bla
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
end-stag
amplifi combo
end-stag
registr studi
registr studi
irrit bowel
monotherapi
soon possibl
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
full data
nuc includ
data phase trial
hbv-infect subject
databas lock file
dose first fabri
announc
diseas patient
dose first patient
phase i/ii trial
dose first patient
phase i/ii trial
part
first data readout
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
enrol tay-
data readout
patient higher dose
top-line result
top-line result
agit
top-lin data
top-lin data
top-lin data
submiss attr-
readout pivot six-
data attribut
studi attr-cm
initi phase
trial attr
ind submiss bbp-
congenit
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
readout phase i/ii
trial
complet submiss
mocd
first patient enrol
nda submiss
initi phase i/ii
clinic trial
readout phase i/ii
trial achondroplasia
trial adjuv
initi phase
gorlin syndrom
initi phase iib trial
data readout
phase ii trial
data phase
mainten trial
pamiparib
data ovarian
cancer late
data phase trial
tislelizumab vs
esophag
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
data phase trial
tislelizumab global
trial r/r
data phase trial
zanubrutinib vs br
inelig fcr
data phase
pivot trial gazyva /-
zanubrutinib r/r fl
updat wm mcl
cll
wm base global
earli
data phase trial
zanubrutinib vs
imbruvica r/r wm
analysi phase
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
phase head head
present
clinic data
present
initi phase
present clinic
data
clinic studi
patient scd
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
file european
approv lentiglobin
patient tdt
decis submit bla
acceler
us eu file
os data present
submit nda
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
present initi data
phase pioneer
trial
submit nda blu-
ret fusion
submit nda blu-
ret mutant
updat data
trial ret fusion
 day investor
monotherapi
readout nash
submit nda file
seladelpar pbc
enrol period
studi pbc
phase data
enhanc studi pbc
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
tecentriq
pivot data
transcend studi
fda japan
data phase
potenti snda file
rubraca mcrpc
base
data phase trial
rubraca opdivo
data phase
trial
therapy/chemo
mcrpc brca
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
data phase
trial
therapy/chemo
mcrpc brca
updat data
trial
rubraca mcrpc
potenti snda file
zejula ovarian
advanc
updat data
expans trial gist
phase
invictu trial
potenti initi data
ripretinib
gist base
atop dermat
interim readout
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
attribute-cm
attribute-cm studi
treatment allerg
start first us district
litig trial begin
potenti approv
tazemetostat es
submit nda
tazemetostat
initi phase trial
agvhd
full safeti efficaci
readout trial
agvhd
initi phase trial
sever
poc trial
sever asthma
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
phase trial dmd
phase trial lapc
initi phase ii
eu file
japan approv dd
present asn
us file
endometri
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
safeti filgotinib
phase result
approv mcl
file fda regulatori
phase ii result
proof concept top-line
proof concept top-line
futil analysi
proof concept top-line
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
proof concept trial
submit nda nash
potenti approv
launch nash
report result
phase studi pbc
resolve-it studi
initi phase studi
elafibranor pbc
lg
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
phase i/iia proof
data cmv trial
phase cmv trial
concept data hpv
 start ind enabl
vomit
start arbitrag period
gener emend iv
manag step
resolv
trial initi htx-
clariti
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
readout revers
submit nda file
oca nash
launch nash
complet enrol
revers studi
heme
heme
aml bpdcn
phase ii dose
potenti data
trial r/r fl
potenti data
trial r/r mcl
potenti data
trial r/r mzl
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
data phase
trial
data phase
trial steroid
data phase
trial steroid
data phase
trial
bladder cancer
expect nda file
data phase true-
ad trial topic
ruxolitinib mild-
ntm caus
initi end-
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
non-smal cell
phase -- data
prevent
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
prevent veno-
announc
visibl resolut
erwinas suppli
issu licens
narcolepsi
narcolepsi
sleepi es
apnea osa
aml /aml
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
complet dose-
updat data
scchn
initi proof-of-
addit data
medic meet
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
european societi
meet sept
preced
dyslipidemia studi
nash phase trial
initi phase studi
phase ii studi
scchn combin
pd-
initi data phase ii
initi data phase ii
initi data phase ii
phase studi
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
fda approv ani
corticotropin
complet enrol
complet enrol
complet enrol
introduct new
appeal decis
start first us district
pathway file
begin file ind
new pipelin asset
complet enrol
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
announc
partnership ex us
control arm data
data keytruda
chemo bladder
cancer
elig plat
data keytruda mono
msi-h dmmr
data keytruda
chemo sclc
data keytruda
chemo tnbc
data keytruda mono
nmibc unrespons
bcg could support
data
infant
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
dose initi
select go-forward
potenti
rare solid
updat dose-
includ
initi clinic data
kra
concept data cpi
interim data orr
phase combo
opdivo cpi refractori
initi data
combin
opdivo pre-surg
rcc hnscc
start phase adult
fda
registr pathway
adult ped
file snda partner
updat data
bempeg nivo
melanoma
follow
init registr
trial bempeg nivo
sclc tnbc
colorect gastric
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
data bempeg nivo
data bempeg nivo
data bempeg nivo
rcc
data bempeg nivo
tnbc
expir
approv
delay fda
american colleg
aml
present vivo
insert data
improv data
submiss ind mid-
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
primros trial
primros trial
feedback implant
result implant
interim data first
updat data
top-lin result hip
top-lin result
top-lin result
studi pediatr
cardiovascular spine
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
nausea
vomit due
post-op
phase initi
acut skin
europ
top line data two
announc
janssen decid
whether recal
american colleg
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
addit data
phase studi
process
select trial single-
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
preliminari safeti
combo
egfr-
announc
patient fail tki
pk/pd translat
escal
year end
complet enrol
year end
formul
safeti
phase
phase
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
phase data
monotherapi
combin
submiss ind
form batten
top-lin data open-
retreat studi
top-lin data
phase cohort data
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
updat timelin
bla file ev r/r
cpi platinum
base trial
data tv phase
innovatv trial
top-line data
metastat
potenti nda file
tucatinib mbc
base
data investig
herceptin
initi solid
formul pku pt
data mono-
cohort
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
preclin studi
submit data
studi fda
arbitr
commenc
resolut expect
approv china
expect
revis label risk
reduct all-caus
mortal compar
anoro ellipta
patient copd
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
result phase
on-going phase
select ind
select ind
ind file
select ind
initi
combin studi
data singl agent
top-line data
start newli
solid tumor
updat
phase ib/iia proof
top-line result
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
top-line result
start phase
start phase
interim data phase
portion
trial nsclc
updat data
phase portion
trial
initi data phase
trial
present tpx-
poster esmo
lid parkinson
analysi studi
expect file ind
x-ald
nash phase
trial
initi phase trial
nash
pre-ind meet gi
divis fda
nda file cf
patient year
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
ema file cf
patient year
evalu abil
reduc
protein level
studi patient
report clinic data
peopl two
mutat
trial design
efficaci dystrophin
result seek
interim analysi
inpati portion
drug agent
type event
event trial detail
known
up/down
svbl view
svbl view
price target base simpl averag three
risk view outlook valuat includ major
approach believ reason basi valu stock
chang price outlook reimburs coverag label
today approach simpl price earn multipl
competit posit humira compani main product risk
compar larg biopharmaceut compani price sale multipl
includ commerci develop disappoint compani
larg cap peer compani stock discount cash flow dcf
follow-on program inflammatori diseas imbruvica venclexta
appli peer ep revenu multipl use averag larg cap larg
expand hematolog malign well competit
molecul therapeut compani mid-term growth tail risk celg
posit compani next-gener hcv therapi also
compani remain highli lever commit grow dividend
multipl appli current ep estim
reduct forecast ebitda due neg busi trend
give valu use revenu multipl
would place compani capit alloc strategi dividend growth
similar compani consensu sale appli
risk opportun upsid expect includ stronger-
revenu estim give valu lastli
than-expect price volum share humira emerg
dcf valuat given wacc termin cash flow growth rate
tangibl demand underappreci element compani
begin humira biosimilar entri give present valu
early-to-mid stage pipelin asset potenti label expans
averag three method current price target
opportun late stage opportun
pt base sotp analysi forecast cash flow
nuplazid rx rebound neg news new indic
discount rate
nuplazid work trofinetid rett syndrom mani new
competitor may steal share
price target base discount cash
risk view outlook valuat alnylam includ major
flow methodolog forecast sale onpattro
chang price reimburs coverag unit state
basi probability-weight scenario analysi risk-adjust sale
europ rare diseas drug onpattro compani key
pipelin agent givosiran lumasiran risk-adjust royalti
pipelin drug givosiran lumasiran forecast
partner program fitusiran inclisiran explicitli model expens
onpattro also subject risk better-than-
result cash flow assum discount rate
expect market share inotersen tafamidi unmodel
consist compani coverag univers revenu
competit entrant use disrupt technolog gene edit
gener approv product wholli own independ
risk alnylam includ clinic regulatori disappoint
commerci least one end-market termin growth rate
pipelin excess factor probabl adjust
addit factor net cash balanc valuat
addit onpattro sale profit fail match estim
dilut financ beyond forecast model may requir
order support futur commerci oper clinic develop
pipelin agent
pt base dcf analysi forecast cash
risk valuat includ sticki market share makena
flow use wacc termin growth rate
subcutan auto injector faster signific gener im
makena penetr potenti chang regulatori approv and/or
societi guidelin makena follow neg phase data earlier
gener competit ferahem slower-than-expect uptak
intrarosa vyleesi clinic risk ciraparantag
price target inc base averag
risk view outlook valuat includ major
three approach believ reason basi valu
chang label price reimburs coverag
stock today approach simpl price earn multipl
compani legaci product failur compani growth
larg cap us eu larg cap biopharma stock
portfolio achiev futur sale forecast risk includ
sni rhhbi gsk nv celg price sale
develop delay disappoint earlier stage pipelin asset
multipl larg cap biotechnolog pharma compani
earlier signific eros compani legaci product
novo nv celg discount cash
biosimilar innov competit shortfal compani effort
flow dcf use rel multipl larg cap biopharma compani
improv oper margin would also materi affect outlook
ep appli ep estim amgen
valuat would larg dilut acquisit therapeut area
give one year futur valu use establish larg cap
platform
futur revenu multipl sale appli
revenu forecast give futur valu
final dcf valuat base current outlook
compani exist product probability-weight revenu
contribut late-stag pipelin program discount
compani wacc give fair valu today averag
three approach give price target
amrn pt base dcf forecast cash flow
risk amrn valuat includ neg adcom vote
use wacc termin growth rate
delay snda approv tg boundari expand label turn
narrow current assumpt gener win vascepa
patent litig trial prompt earlier entri vs estim
epanova yield posit result strength trial becom
meaning competitor vascepa manufactur may increas
abl support peak sale estim
use weight averag ev/ebitda multipl
addit competit entrant key product franchis gx
ebitda deriv pt valuat includ cash
vagifem voltaren gel levothyroxin continu delay new
outflow base estim pv potenti damag
product launch like gx copaxon gx nuvar even
relat on-going opioid gener price fix lawsuit
signific eros base busi
arql price target arql base blend dcf
arql pipelin program face clinic regulatori develop risk
analysi revenu multipl analysi assign probability-weight us
well commerci intellectu properti risk arql also face
sale arq chronic lymphocyt leukemia cll probabl
execut risk financi risk arql may addit financ
success assum royalti ex-u sale futur
need turn cash flow posit
partnership also assign valu probability-weight royalti arq
intrahepat cholangiocarcinoma icca probabl success
probability-weight sale arq proteu syndrom
probabl success also assign valu probability-weight us
sale arq breast cancer endometri cancer
probabl success assum royalti ex-u
sale futur partnership addit opportun expand
develop arq addit indic repres upsid
estim use discount rate termin growth rate
price target base dcf
risk view outlook valuat assembl includ
methodolog cash flow termin valu
major clinic failur competitor core inhibitor could
forecast risk-adjust sale assum
lower probabl success class potenti commerci
discount rate base compani wacc addit factor
outlook could also diminish novel hbv
cash balanc valuat
therapi produc superior clinic data drug profil
accept physician patient regardless competit
risk uptak new approv medicin hbv minim
payer creat arduou restrict prevent access assembl
never achiev product revenu posit cash flow futur period
provid adequ return current invest addit
dilut financ like requir order support futur commerci
oper clinic develop
auph deriv per share price target auph share month
risk auph primarili relat clinic develop
base dcf analysi use discount rate termin
voclosporin sinc auph one product pipelin
growth rate fulli generic revenu ascrib
data qualiti time setback could impact stock significantli auph
probabl success po voclosporin lupu nephriti ln
small cap biotech compani may need access capit
po focal segment glomerular sclerosi fsg
market financ risk also possibl
price target base discount cash
risk view outlook valuat bridgebio includ
flow methodolog forecast cash flow assign
major chang price reimburs coverag unit state
termin growth rate discount rate factor net
europ would affect key pipelin drug infigratinib
cash balanc project sale ttr amyloidosi basi
eido qed two largest valuing-driv
probability-weight scenario analysi sale infigratinib
subsidiari compani potenti clinic setback
pipelin asset risk-adjust basi
commerci under-perform infigratinib would
disproport decreas valuat estim addit
subsidiari compani integr bridgebio manag
complex may grow time increas risk addit new
unmodel competit entrant could potenti compet market
share development candid reduc futur cash
flow project
bgne use risk-adjust sum-of-the-part methodolog valu beigen
 clinic risk clinic trial failur beigen pipelin asset
pt examin clinic regulatori commerci
especi later stage drug includ zanubrutinib tislelizumab
risk opportun individu indic region
pamiparib commerci risk greater anticip competit either
assign probabl success account likelihood achiev
domest china intern could impact perceiv valu
revenues/expens risk-adjust sum-of-the-part analysi
beigen pipeline-clin risk failur obtain regulatori approv
appli discount rate cash flow gener
compani product unit state europ china would
beigen asset determin total net present valu risk-adjust
like diminish valu beigen pipelin
asset total npv reflect remain clinic regulatori risk
program
estim fair valu month share sum-of-
risk includ success market initi identifi patient
part dcf analysi attribut naglazym
naglazym kuvan brineura vimizim depend sni
kuvan aldurazym vimizim/galn
market aldurazym program earlier stage
firdaps palynziq/peg-p vosoritid
develop entail higher clinic regulatori develop
probability-weight brineura valrox
probability-weight remaind potenti earli pipelin
products/bmrn platform net cash
deriv one-year pt base blend dcf
clinical-stag compani risk includ clinic regulatori
analysi revenu multipl analysi assign valu probability-
weight sale avacopan po anca-associ vascul
data readout even though evalu multipl indic
aav glomerulopathi hidraden
guarante program succeed
suppurativa hs sale po focal segment
understand complement system diseas still evolv
glomerulosclerosi fsg addit indic
success particular indic may translat success
clinic asset earlier-stag candid repres upsid
indic full safeti profil includ long-term exposur
estim matur clinical-stag compani use discount
remain tbd clinic risk associ clinic candid
rate termin growth rate repres market
month price target base dcf
risk view outlook valuat eido includ major
methodolog forecast risk-adjust sale explicitli model
chang price reimburs coverag unit state
expens result cash flow assum
europ rare diseas drug forecast also
discount rate consist clinical-stag pre-revenu compani
subject risk better-than-expect market share perform
coverag univers termin growth rate addit
includ net cash balanc valuat
gene edit greater-than-expect success
penetr wtttr and/or ttr-cm segment risk eido
includ unexpect off-target safeti risk regulatori
requir approv requir greater-than-expect pivot studi
durat sampl size unfavor statist analysi method
case eido may requir dilut financ forecast
price target base ebitda
delay gener competit vasostrict adrenalin opioid litig
ev/ebitda multipl valuat incorpor addit
liabil larger expect delay time new gx launch
payment relat mesh product liabil valuat
lower-than-expect growth steril inject higher-than-expect
also includ cash outflow base estim pv
growth xiaflex cellulit opportun may larg
potenti damag relat on-going opioid gener price fix
price target base dcf
clinic risk includ abil roxadustat approv base
methodolog includ probability-weight roxadustat royalti
long-term cardiovascular cv outcom trial versu erythropoietin-
mileston payment astella eu japan azn us row
stimul agent esa phase dialysi trial placebo
roxadustat profit-shar azn china assum
phase non-dialysi trial unknown safeti issu associ phd
probabl success po dialysis-depend non-
inhibit hif stabil regulatori commerci risk associ
dialysi depend chronic kidney diseas ckd indic variou
bring new class market variou territori particularli
geographi current model po pamrevlumab idiopath
china uncertain size potenti anemia market particularli outsid
pulmonari fibrosi ipf pancreat cancer assum
dialysi set unknown reimburs landscap us
discount rate believ appropri given probability-
regard inclus roxadustat prospect payment
weight sale includ termin growth rate beyond
aka bundl pamrevlumab safeti signal
underwhelm result phase trial ipf pancreat cancer
manufactur develop setback delay pamrevlumab
compar project launch date
price target inc base
risk view outlook valuat gilead includ major
averag four approach believ reason basi
chang label price reimburs coverag
valu stock today approach trough price earn
compani exist hiv hcv product emerg
multipl larg cap slow-growth medic product busi long term
aggress price discount rebat valu eros hiv
revenu multipl larg cap medic product stock slow growth
hcv categori current forecast failur
outlook sum part valuat exist franchis discount
compani princip pipelin asset selonsertib nash filgotinib
ra ibd advanc develop commerci
multipl slow-growth medic product stock celg
opportun better perform valu expect
appli ep estim gilead give
includ delay limit develop profil adopt
price altern appli slow-grow large-cap biopharma
competit hiv product success develop underappreci
element compani portfolio fxr agonist gs-
revenu estim deriv impli valu
inhibitor follow-on car-t indic stronger-than-
impli one-year price target use sum part valuat
expect convers current hiv patient gilead next gener
exist franchis get price consist primarili price
compani hiv franchis hcv product lastli
dcf use forecast free cash flow appli
growth rate termin cash flow forecast discount
valu back present wacc give present valu
averag four approach price target
gnft arriv price target use probability-weight methodolog
product concentr elafibranor account entir portion
dcf valu use discount rate termin growth rate
valuat genfit asset develop outsid
forecast potenti launch nash peak adjust revenu
elafibranor clinic delay poor profil nash pbc creat
billion probabl success
substanti volatil elafibranor full product profil defin
base case increment scenario peak adjust revenu
remain clinic studi unclear differenti compar
billion meaning scenario
oca late-stag asset nash next year
substanti chang view medicin ultim potenti poor
uptak address market limit access product
real risk particularli respect requir biopsi
confirm nash diagnosi competit landscap nash quickli
becom crowd robust pipelin chase opportun fxr
inhibitor ppar agonist drug develop could see
greater-than-expect uptak approv limit market
opportun elafibranor financ risk genfit held debt
genfit capit risk like larg investor
anticip dilut financ activ prior reach
profit specif expect see anoth larg equiti rais within
next two year genfit continu burn cash
launch elafibranor nash note lead dilut
deriv one-year pt base blend dcf
clinical-stag compani risk includ clinic regulatori
analysi revenu multipl analysi assign valu probability-
financi heavy-weight valuat add
weight sale po hereditari angioedema
signific binari risk head data readout favor pk/pd may
royalti stream po diabet macular edema dme
translat differenti clinic profil patient eventu
addit program indic collabor may present upsid
uptak prophylaxi therapi takhzyro haegarda
estim matur clinical-stag compani use
repercuss size acute/on-demand market merck
discount rate termin growth rate repres
may exercis option in-licens dme put potenti
mileston royalti payment risk futur program
bring forth share risk irrespect progress
success earlier agent safeti profil
includ long-term exposur plasma kallikrein pkal inhibitor
remain tbd commerci uptak and/or evolut competit
landscap impact legaci entrant and/or gener drug advers
price target base blend dcf analysi
earli stage biotech compani face signific clinic
revenu multipl analysi assign valu probability-weight us
regulatori develop risk well commerci risk also face
sale selinexor multipl myeloma probabl success
execut risk financi risk vast major valuat
rrmm treat prior boston probabl success
base selinexor compani lead clinic stage product candid
rrmm treat prior storm diffus larg cell lymphoma
potenti setback due possibl safeti and/or efficaci relat issu
probabl success dlbcl sadal assum royalti
selinexor could signific impact valuat
ex-u sale potenti partnership also assign valu
dedifferenti liposarcoma probabl success dcf
analysi use discount rate termin growth rate
price target base blend dcf
pipelin program face clinic regulatori develop risk
analysi revenu multipl analysi assign valu probability-
well commerci intellectu properti risk also face
weight sale margetuximab metastat breast cancer
execut risk financi risk may addit financ
metastat breast cancer neoadjuvant/adjuv breast
need turn cash flow posit
cancer gastroesophag cancer probability-weight
sale enoblituzumab scchn earli stage bispecif
pipelin repres upsid estim use discount rate
termin growth rate
deriv pt use dcf analysi base upon
acthar growth may miss exceed expect may
discount rate termin valu includ charg
greater-than-expect delay entri acthar competitor
lawsuit opioid litig
durabl perform acthar could win appeal
also lack visibl around potenti liabil could
result opioid litig outcom could result
share trade price target
price target base dcf use
keytruda-specif risk increment scientif innov io may
wacc account net cash project revenu gener
continu prove difficult initi burst fail
rang outcom keytruda io asset deriv
pursu most-promis add-on therapi bd competitor
mont carlo simul entir io industri pipelin
reli deeper intern pipelin price reimburs relat risk
develop path iter model growth vaccin
hiv franchis consensu estim vertic
model risk commerci pharma keytruda exposur
medicar part could make particularli sensit us health-
prefer high-volum high-reb option major leg keytruda
competit moat risk reimburs enhanc oversea
re-negoti drug switch routin practic low-cost
local altern china could drive price one keytruda
pt base sotp analysi forecast cash flow
small number patient phase orphan epilepsi
discount rate
trial possibl ganaxolon success larg pivot
trial allopregnanolon biomarker-driven strategi may
success marinu abl partner program instead
rais money ramp spend significantli execut
go alon strategi larger better financially-back
compani launch first two product market
slower-than-expect neg clinic develop progress
marinu clinic program faster-than-expect loss patent
protect assum
pt includ sitravatinib revenu ex-u sitravatinib
 clinic risk mirati multipl drug candid clinic develop
royalti use checkpoint inhibitor cpi relapsed/refractori non-smal
includ sitravatinib trial produc clinic data
cell lung cancer nsclc bladder cancer pt also includ us
disappoint rel investor expect repres risk
ex-u revenu revenu kra cancer
valuat regulatori risk regulatori approv requir
includ nsclc colorect cancer pancreat cancer
commerci prescript drug issu regul result
endometri cancer includ risk-adjust npv per
longer-than-anticip timelin failur gain approv mirati
share mirati earli pipelin includ compani program target
drug would repres risk valuat competit drug
compet mirati pipelin candid could produc superl
methodolog valu examin clinic regulatori
clinic data lead increas competit market less-than-
commerci risk opportun individu indic
anticip uptak product repres risk current
region assign probabl success account likelihood
achiev revenues/expens use wacc termin
valu nopat indic depend
length patent protect account valu beyond
use weight averag ev/ebitda multipl
gener advair opportun may smaller estim
ebitda deriv price target per share valuat
commerci uptak biosimilar may take longer anticip growth
includ cash outflow base estim pv
ou market may slower expect market penetr
potenti damag relat on-going opioid gener price fix
gener copaxon may improv biosimilar neulasta ramp may
slower estim remedi morgantown facil
may take longer allevi reach lower capac current
estim mylan/upjohn deal may yield expect revenu growth
synergi expect
rate share outperform pt leverag
pre-commerci stage compani risk valuat includ clinic
proprietari target therapi bard omav develop novel
trial outcom delay clinic develop regulatori risk prior
therapeut patient rare life-threaten diseas caus
approv reimburs risk post-approv also sinc bardoxolon
dysregul metabol mitochondri function program
omaveloxon first-in-class therapi unforeseen complic
seek either improv upon current standard care ctd-pah
risk may emerg financi perspect clinic develop
becom first-to-market therapi diseas approv therapi
requir signific invest could necessit dilut financ
exist alport syndrom fa mitochondri myopathi
road
conserv project probabl success po bard ctd-
pah due advanc follow rel small phase
residu uncertainti surround mechan action
appropri patient popul howev believ
catalyst trial highli power alport syndrom ascrib
po bard base highli encourag cardin data
extens clinic histori increas estim glomerular filtrat rate
egfr singl endpoint approv ascrib po omav
fa due earlier stage develop rel intract
diseas base posit phoenix data includ
ckd model assign po well po
adkpkd po lgan bardoxolon model
assign credit program potenti revenu gener
collabor pipelin multipl innov product
routin seen clinic stage biotechnolog compani result
develop regulatori market reimburs uncertainti
believ share best valu via dcf analysi use
discount rate termin growth rate yield pt
price target base blend dcf
pipelin program face scientif clinic regulatori
analysi revenu multipl analysi assign valu probability-
develop risk well commerci intellectu properti risk
weight sale rare diseas probabl success
also face execut risk financi risk may
phenylketonuria preclin rare diseas program
addit financ need turn cash flow posit
probabl success homocystinuria refractori gout hyperoxaluria
also assign valu probability-weight sale oncolog
formerli probabl success solid tumor non-
respons therapi probabl success patient
acut myeloid leukemia aml follow hematopoiet cell transplant
hct procedur also assign valu probability-weight sale
royalti preclin program autoimmun diseas probabl
success type diabet probabl success pemphigu
vulgari use discount rate termin growth rate
use risk-adjust sum-of-the-part methodolog valu seattl
commerci risk competit compani develop
genet pt examin clinic regulatori
treatment hodgkin lymphoma breast cancer urotheli cancer
commerci risk opportun individu indic region
clinic risk fail clinic trial compound
assign probabl success account likelihood
develop includ tucatinib enfortumab vedotin
achiev revenues/expens risk-adjust sum-of-the-part
compani earli stage pipelin regulatori risk fda reject seattl
analysi appli discount rate cash flow gener
genet pipelin asset adcetri tucatinib enfortumab vedotin
seattl genet asset determin total net present valu
compani earlier stage asset
risk-adjust asset total npv reflect remain clinic
regulatori risk program
deriv pt use discount cash flow dcf analysi
solid develop pan-genotyp gene therapi drug candid
assum discount rate termin growth rate model
could potenti address dmd pt minu pt neutral
incorpor lead asset gene therapi dmd
antibodi gene therapi candid platform come
antibodi dmd current estim
safeti efficaci risk although preclin data seem convinc
gross peak sale respect
platform earli stage develop clinical/regulatori
account risk clinic regulatori drug develop
probabl success estim rang
us eu us eu
recept unanticip complic could impact
valuat paramet reflect promis preclin data view off-set
uncertain safety/ efficaci profil candid still
rel earli stage develop
teva price target base ebitda
continu delay new gener opportun slower-than-anticip
ev/ebitda multipl valuat includ cash outflow
ramp ajovi headlin risk gener price fix opioid
base estim pv potenti damag relat
lawsuit could result teva trade lower price target addit
on-going opioid gener price fix lawsuit
delay gener competit copaxon proair along faster
growth austedo could result teva trade price target
price target base dcf fc sale
fc trial true binari event signific
recurr glioma base probabl success
upside/downsid risk rate pt upon read-out final analysi
wacc po base typic probabl
success trial gbm cut half reflect lower odd studi
pass second interim believ odd weight heavili
success would expect share trade net cash
event failur estim year-end event
trial success believ share price could reach equival
dilut market cap project uptak recurr glioma
addit upsid driven po newli diagnos gbm well
arriv price target use probability-weight methodolog
nash current carri entir portion price target
dcf-depend valu account differ commerci scenario
potenti indic outsid nash clinic delay
keep probabl success constant nash
poor profil nash creat substanti volatil full
ascrib valu pipelin asset largest compon
product profil defin remain clinic studi
price target come likelihood achiev
unclear differenti compar oca elafibranor
meaning commerci profil nash un-differenti commerci
asset read phase next year substanti
profil contribut cash overal price target breakthrough
chang view medicin ultim potenti poor uptak
profil add base substanti upsid potenti assign
address market limit access product real risk
probabl achiev breakthrough profil nash
particularli respect requir biopsi confirm nash
diagnosi nash quickli becom crowd robust pipelin
chase opportun fxr inhibitor ppar agonist drug
develop could see greater expect uptak approv
limit market opportun
deriv price target share use discount cash flow
risk view outlook valuat includ major
analysi forecast cash flow assign
chang price reimburs coverag unit state
termin growth rate discount rate account wave share
europ rare diseas drug revenu forecast subject
global profit share collabor takeda huntington
risk better-than-expect market share compet product
diseas al frontotempor dementia ftd program use
huntington diseas includ limit model oligo
probabl success hd po famili al ftd
competitor dmd includ limit approv product
neither program enter market prior also includ revenu
announc pipelin product other unmodel
wave wholli own duchenn muscular dystrophi dmd program
competit entrant use disrupt technolog gene edit
probabl success dcf valuat use
gene therapi risk includ clinic regulatori disappoint
drug candid excess factor probabl
stock option
adjust addit drug candid sale profit fail
match estim dilut financ may requir order
support futur commerci oper clinic develop pipelin
pt base dcf analysi forecast cash flow
risk valuat includ potenti competit larger
use wacc termin valu wacc
player xeri glucagon rescu execut commerci
rang late stage pre-commerci compani coverag
risk launch market adopt expans may take longer
anticip potenti need addit cash rais although
could mitig non-dilut financ regulatori risk
xeri pen may see delay fda approv
price target base npv methodolog assign
risk valuat includ clinic regulatori commerci
probabl success po luspatercept md
competit risk compani import pipelin product
md transfus depend thalassemia non-
luspatercept well develop disappoint
transfus depend thalassemia assign po
phase result luspatercept posit acceleron
candid sotatercept pah fshd deriv
program remain rel earli stage therefor signific
month price target discount probability-weight annual cash flow
small/mid-cap biotech discount rate assum
turn profit compani also face risk associ
termin growth rate cash flow beyond
continu access capit market given continu oper
loss financ invest
pt base sotp analysi forecast cash flow
fintepla lg data need success broaden label allow
post-exclus fintepla discount rate
physician use refract patient fintepla cv safeti signal could
issu real world
